A final proviso should be added to these studies given the recent report from Talebian et al., who were driven to investigate the impact of the CD200 blockade in what is thought to be a more clinically relevant model for human melanoma, namely CD200+ Yumm1.7cells [97]. The gene discussed is CD200; the disease is melanoma.